In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...
The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain ...
He’s openly criticized the FDA and has called for an end to the regulatory oversight of many health products, including ...
GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...
With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
LEMSIP and other popular cold and flu tablets should be pulled from Britain’s shelves because they don’t work, experts have ...
New York Post on MSN3d
FDA proposes ending use of popular decongestant in cold medicinesThe US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...
Phenylephrine:CVS pulls cold medicines with the ingredient Companies such as Procter & Gamble and GSK were among several accused in ... For now, companies may continue to market drug products ...
Fitch Solutions has predicted that the naira would slide to as low as N1,993 per dollar in 2028, severely impacting Nigeria’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback